argenx SE (ARGX) Q3 2021 Earnings Call Transcript

·36-min read
argenx SE (ARGX) Q3 2021 Earnings Call Transcript

The Bullous Pemphigoid trial is on track to start by the end of this year, and Myositis is expected to start during the first quarter of 2022, now that we have wrapped up our FDA consultations, and these are depicted on Slides 10 and 11. Through our collaboration with Zai Lab, we are also planning to launch proof-of-concept trials in additional indications.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting